AFFYMAX/HGS AUTOMATED SCREENING/GENOMICS COMBINATION WOULD BE ONE OUTCOME OF GLAXO/SMITHKLINE MERGER; R&D CONSOLIDATION LIKELY TO SPUR START-UPS
The 1995 merger of Glaxo and Wellcome is an apt model for the likely impact of a consolidation of SmithKline Beecham and Glaxo Wellcome's R&D operations: substantial downsizing by the newly merged firm accompanied by a flowering of smaller start-ups and new spin-offs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth